Skip to main content

Table 1 Overview of breast cancer trials - the 'doubly tested trials'

From: Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?

  Stage IV response rates Adjuvant setting DFS hazards
Tamoxifen 30 to 40% 0.60 to 0.70
Cyclophosphamide (vincristine prednisolone) 40 to 80% 0.70
Anthracyclines versus cyclophosphamide 20 to 30% 0.80
Taxanes versus anthracyclines 20 to 30% 0.81
Aromatase inhibitors (letrozole) versus tamoxifen 30 to 40% 0.57
Trastuzumab versus placebo 40 to 50% 0.42 to 0.54
Curability 0% 15 to 40%
  1. RCT, randomized controlled trial.